bioAffinity Technologies (BIAF) Shares Outstanding (Weighted Average) (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $1.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $1.3 million, down 89.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 89.53% YoY), and the FY2025 annual result was $1.7 million, up 319.84% from the prior year.
• Shares Outstanding (Weighted Average) held at $1.3 million in Q1 2026 per BIAF's latest filing, from $1.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $28.2 million in Q2 2025 and troughed at $409937.0 in Q4 2024.
• A 5-year average of $6.4 million and a median of $4.6 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) surged 901.56% in 2022, then tumbled 95.31% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $4.6 million in 2022, then jumped by 88.12% to $8.7 million in 2023, then plunged by 95.31% to $409937.0 in 2024, then surged by 228.95% to $1.3 million in 2025, then dropped by 0.01% to $1.3 million in 2026.
• Business Quant data shows BIAF's Shares Outstanding (Weighted Average) at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.